Mesox Ltd

The pharmaceutical industry has several challenges that hinder the development and manufacture of new drug formulations of bioavailable medicines efficiently and sustainably. Indeed, poor bioavailability affects 70-90% of pipeline drugs and 40% of marketed medicines, contributing to estimated 17% of Phase-I clinical trial failures. One of the common strat...

Long-acting injectable (LAI) drug products offer the potential to transform human health through treatment of a range of diseases. Most of LAI research to date has been invested in exploring new APIs and novel drug cargoes for improved therapeutic effect and better patient compliance. This has led to limited research exploring the science underpinning the...

_**ASD3MAP: Amorphous Solid Dispersion Digital Design and Manufacturing Platform for rapid and resource-efficient development of bioavailable medicines.**_ MESOX Ltd (Lead), in collaboration with Aston University (Partner), propose an 18-month project focussing on the refinement of the Consortium's molecular dynamics models through the integration of at m...

MESOX developed a novel particle carrier technology for enhancing the bioavailability of medicines. The carrier has nanopores within its structure and each nanopore behaves like a nano-container for drug molecules. When a drug is loaded within a nanopore, it converts to its amorphous solid form which easily dissolves in the patient body. As a result, drug...

We propose to develop a novel medicated dressing containing a molecule that achieves faster diabetes wound healing. This is a problem affecting 450,000 individuals with diabetes in the UK alone. It costs the NHS £900M annually in care (healthcare visits) and treatment costs (antibiotics, bandages etc). We expect our dressing to be able to achieve twice as...